Results & safety

The numbers, and what they do not cover.

Every weight-loss service quotes SURMOUNT-1. Far fewer print the sample size, the comparison arm, the sponsor, or the four reasons their own member average is flattering. All of that is on this page.

See the tirzepatide plan Check your BMI

Published trials

Three papers, quoted as printed

Peer-reviewed, with the citation on each card so you can go and read the paper rather than take our summary of it.

SURMOUNT-1n = 2,539 · 72 weeks

−20.9%Mean body weight reduction on tirzepatide 15 mg versus −3.1% on placebo, with 96% of participants losing at least 5%.Jastreboff et al., N Engl J Med 2022;387:205

SURMOUNT-3n = 579 · 72 weeks

−18.4%Additional weight lost after a 12-week lifestyle lead-in, versus a 2.5% regain on placebo — medication beat willpower alone.Wadden et al., Nature Medicine 2023

SURMOUNT-5n = 751 · 72 weeks

Head-to-headTirzepatide produced greater sustained weight reduction than semaglutide in the first direct comparison of the two.Aronne et al., N Engl J Med 2025

Trial figures refer to tirzepatide studied as an adjunct to reduced-calorie diet and increased physical activity, and are quoted from the published papers cited above; they are not results produced by Renu Health or by compounded preparations. Individual results vary. Renu member averages are self-reported weigh-ins and are not a controlled study.

Renu members

Our own six months, with the caveats attached

Average total body weight change across members who completed a full titration and logged monthly weigh-ins. It tracks close to the trial curve, which is reassuring and also exactly what you would expect from a group that stayed on treatment long enough to be counted.

-17%Average at month 6

86%Still on plan at month 6

Start

Month 1

-3%

Month 2

-6%

Month 3

-9%

Month 4

-12%

Month 5

-15%

Month 6

-17%

Not our dataThe SURMOUNT figures are from Eli Lilly-sponsored trials of branded tirzepatide, not from Renu and not from compounded preparations.

Self-reportedRenu member averages come from weigh-ins members log themselves. Nobody is standing over the scale.

Survivor biasThe −17% average is across members who completed a full titration. People who stopped at week six are not in it.

Adjunct, not replacementEvery trial quoted studied the medication alongside a reduced-calorie diet and increased activity, not instead of them.

Why results track dose

The ladder is the treatment.

The 20.9% figure is the 15 mg arm. The 5 mg arm in the same trial reported −15.0%. Nearly all of the variation between members comes down to how far up this ladder they got and how long they stayed there — which is a scheduling problem, not a willpower one.

See the full titration plan

2.5 → 15 mg over 20+ weeks

2.5

7.5

12.5

15 mg

Safety

What actually goes wrong, and when

None of this is a reason not to treat obesity. It is the set of things your doctor is watching for, listed so you can watch for them too.

4 wksBetween doctor reviews

₦0Cost to report a side effect

< 2hMedian reply

The first fortnight after every increaseNausea, constipation and reflux cluster around dose changes rather than spreading evenly. Knowing that is most of the management: eat smaller and earlier for three days after an injection, keep fluid up, and expect it to settle.

Constipation is the one people underestimateIt is the most common reason members feel unwell in month two and it is almost always a fluid and fibre problem stacked on a much smaller food volume. Your doctor will ask about it at every review whether you raise it or not.

Gallbladder disease and pancreatitis are rare and realRapid weight loss of any kind raises gallstone risk. Severe abdominal pain radiating to the back means stop injecting and be seen the same day. That instruction is in your welcome message and on your delivery note for a reason.

Muscle mass is a real cost of fast lossA meaningful share of weight lost on any GLP-1 is lean tissue. Protein intake and resistance work are not optional extras on this programme, and your doctor will raise them before you have asked.

Do not start ifYou have a personal or family history of medullary thyroid carcinoma or MEN2, you are pregnant, breastfeeding or planning to conceive within two months, or you have had pancreatitis. The intake form asks all three, and answering them accurately is the single most important thing you do on this site.

Read all that and still want to start?

Good. That is the right order. The health form takes three minutes and a doctor reviews it the same day.

Start free consultation Read the questions first

Takes ~3 min · No HMO needed · Cancel anytime